Plasmin, urokinase plasminogen activator receptor and amiloride in the nephrotic syndrome

Nephrotic Syndrome: Etiology, Pathogenesis and Pathology

Volumn , Issue , 2015, Pages 11-28

  Trimarchi, Hernán ^a  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

Author keywords

Amiloride; edema; glomerulopathies; nephrosis; plasmin; proteinuria

Indexed keywords

EID: 84955689726     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (116)

1. Abbate M, Zoja C, Remuzzi G. How does proteinuria cause progressive renal damage? J. Am. Soc. Nephrol. 2006;17:2974-2984.
2. Gekle M. Renal tubule albumin transport. Annu. Rev. Physiol. 2005;67:573-594.
3. Orth SR, Ritz E. Nephrotic syndrome. Internist (Berl). 1998;39:1246-1252.
4. Doucet A, Favre G, Deschenes G. Molecular mechanism of edema formation in nephrotic syndrome therapeutic implications. Pediatr. Nephrol. 2007;22:1983-1990.
5. de Zeeuw D. Albuminuria: a target for treatment of type 2 diabetic nephropathy. Semin. Nephrol. 2007;27:172-181.
6. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Chronic Kidney Disease Prognosis Consortium: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 2010;375:2073-2081.
7. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782.
8. Rostoker G, Behar A, Lagrue G. Vascular hyperpermeability in nephrotic edema. Nephron. 2000;85:194-200.
9. Lourdel S, Loffing J, Favre G, Paulais M, Nissant A, Fakitsas P, Creminon C, Feraille E, Verrey F, Teulon J, Doucet A, Deschênes G. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis. J. Am. Soc. Nephrol. 2005;16:3642-3650.
10. Audigé A, Yu ZR, Frey BM, Uehlinger DE, Frey FJ, Vogt B. Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome. Clin. Sci (Lond). 2003;104:389-395.
11. Hricik DE, Chung-Park M, Sedor JR. Glomerulonephritis. N. Engl. J. Med. 1998;339: 888-899.
12. Bengrine A, Li J, Hamm LL, Awayda MS. Indirect activation of the epithelial Na+ channel by trypsin. J. Biol. Chem. 2007;282:26884-26896.
13. Theilig F, Kriz W, Jerichow T, Schrade P, Hhnel B, Willnow T, Le Hir M, Bachmann S. Abrogation of protein uptake through megalin-deficient proximal tubules does not safeguard against tubulointerstitial injury. J. Am. Soc. Nephrol. 2007;18:1824-1834.
14. Lötscher M, Kaissling B, Biber J, Murer H, Levi M. Role of microtubules in the rapid regulation of renal phosphate transport in response to acute alterations in dietary phosphate content. J. Clin. Invest. 1997;99:1302-1312.
15. Tian YC, Fraser D, Attisano L, Phillips AO. TGF-beta1-mediated alterations of renal proximal tubular epithelial cell phenotype. Am. J. Physiol. Renal Physiol. 2003;285: F130-142.
16. Svenningsen P, Bistrup C, Friis UG, Bertog M, Haerteis S, Krueger B, Stubbe J, Nørregaard Jensen O, Thiesson HC, Uhrenholt TR, Jespersen B, Jensen BL, Korbmacher C, Skøtt O. Plasmin in Nephrotic Urine Activates the Epithelial Sodium Channel. J. Am. Soc. Nephrol. 2009;20:299-310.
17. Kim SW, de Seigneux S, Sassen MC, Lee J, Kim J, Knepper MA, Frakiaer J, Nielsen S. Increased apical targeting of renal ENaC subunits and decreased expression of 11betaHSD2 in HgCl2-induced nephrotic syndrome in rats. Am. J. Physiol. Renal Physiol. 2006;290:F674-687.
18. Deschênes G, Wittner M, Stefano A, Jounier S, Doucet A. Collecting duct is a site of sodium retention in PAN nephrosis: a rationale for amiloride therapy. J. Am. Soc. Nephrol. 2001;12:598-601.
19. Kleyman TR, Cragoe EJ Jr. Amiloride and its analogs as tools in the study of ion transport. J. Membr. Biol. 1988;105:1-21.
20. Edwards S, Lalor PF, Tuncer C, Adams DH. Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner. Br. J. Cancer. 2006;95:1545-1554.
21. Wu S, Murrell GA, Wang Y. Interferon-alpha (Intron A) upregulates urokinase-type plasminogen activator receptor gene expression. Cancer Immunol. Immunother. 2002; 51:248-254.
22. Wang Y, Jones CJ, Dang J, Liang X, Olsen JE, Doe WF. Human urokinase receptor expression is inhibited by amiloride and induced by tumor necrosis factor and phorbol ester in colon cancer cells. FEBS Lett. 1994;353:138-142.
23. Wei C, Möller CC, Altintas MM, Li J, Schwarz K, Zacchigna S, Xie L, Henger A, Schmid H, Rastaldi MP, Cowan P, Kretzler M, Parrilla R, Bendayan M, Gupta V, Nikolic B, Kalluri R, Carmeliet P, Mundel P, Reiser J. Modification of kidney barrier function by the urokinase receptor. Nat. Med. 2008;14:55-63.
24. Zhang B, Xie S, Shi W, Yang Y. Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria. Nephrol. Dial. Transplant. 2012; 27:1746-1755.
25. Trimarchi H. Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plasminogen activator receptor. World J. Nephrol. 2013;2:103-110.
26. Gadau J, Peters H, Kastner C, Kühn H, Nieminen-Kelha M, Khadzhynov D, Krmer S, Castrop H, Bachmann S, Theilig F. Mechanisms of tubular volume retention in immune-mediated glomerulonephritis. Kidney Int. 2009;75:699-710.
27. Joles JA, Willekes-Koolschijn N, Braam B, Kortlandt W, Koomans HA, Dorhout Mees EJ. Colloid osmotic pressure in young analbuminemic rats. Am. J. Physiol. 1989; 257:F23-F28.
28. Koomans HA, Kortlandt W, Geers AB. Lowered protein content of tissue fluid in patients with the nephrotic syndrome: observations during disease and recovery. Nephron. 1985;40:391-395.
29. Koomans HA, Geers AB, Dorhout Mees EJ, Kortlandt W. Lowered tissue-fluid oncotic pressure protects the blood volume in the nephrotic syndrome. Nephron. 1986; 42:317-22.
30. Fauchald P, Noddeland H, Norseth J. Interstitial fluid volume, plasma volume and colloid osmotic-pressure in patients with nephrotic syndrome. Scand. J. Clin. Lab. Invest. 1984;44:661-667.
31. Aukland K, Nicolaysen G. Interstitial fluid volume: local regulatory mechanisms. Physiol. Rev. 1981;61:556-643.
32. Joles JA, Koomans HA, Kortlandt W, Boer P, Dorhout Mees EJ. Hypoproteinemia and recovery from edema in dogs. Am. J. Physiol. 1988;254:F887-894.
33. Jennette JC, Falk RJ. Adult minimal change glomerulopathy with acute renal failure. Am. J. Kidney Dis. 1990;16:432-437.
34. Furuya R, Kumagai H, Ikegaya N, Kobayashi S, Kimura M, Hishida A, Kaneko E. Reversible acute renal failure in idiopathic nephrotic syndrome. Intern. Med. 1993;32: 31-35.
35. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercise. Case 4-1982. Sudden onset of renal failure and the nephrotic syndrome in a middle-aged woman. N. Engl. J. Med. 1982;306:221-231.
36. Siddall EC, Radhakrishnan J. The pathophysiology of edema formation in the nephrotic syndrome Kidney Int. 2012;82:635-642.
37. Jankun J, Skrzypczak-Jankun E. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride. Cancer Biochem. Biophys. 1999;17:109-123.
38. Ferraris GM, Sidenius N. Urokinase Plasminogen Activator Receptor: A Functional Integrator of Extracellular Proteolysis, Cell Adhesion, and Signal Transduction. Semin. Thromb. Hemost. 2013;39:347-355.
39. Meijers B, Maas RJH, Sprangers B, Claes K, Poesen R, Bammens B, Naesens M, Deegens JKJ, Dietrich R, Storr M, Wetzels JFM, Evenepoel P, Kuypers D. The soluble urokinase receptor is not a clinical marker for focal segmental glomerulosclerosis. Kidney Int. 2014;85:636-640.
40. Wada T, Nangaku M, Maruyama S, Imai E, Shoji K, Kato S, Endo T, Muso E, Kamata K, Yokoyama H, Fujimoto KB, Obata Y, Nishino T, Kato H, Uchida S, Sasatomi Y, Saito T, Matsuo S. A multicenter cross-sectional study of circulating soluble urokinase receptor in Japanese patients with glomerular disease. Kidney Int. 2014;85:641-648.
41. Sinha A, Bajpai J, Saini S, Bhatia D, Gupta A, Puraswani M, Dinda AK, Agarwal SK, Sopory S, Pandey RM, Hari P, Bagga A. Serum-soluble urokinase receptor levels do not distinguish focal segmental glomerulosclerosis from other causes of nephrotic syndrome in children. Kidney Int. 2014;85:649-658.
42. Sier CF, Sidenius N, Mariani, Aletti G, Agape V, Ferrari A, Casetta G, Stephens RW, Brünner N, Blasi F. Presence of urokinase-type plasminogen activator receptor in urine of cancer patients and its possible clinical relevance. Lab. Invest. 1999; 79:717-722.
43. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Hoyer-Hansen G, Ronne E, Dybkjaer E, Danø K, Brünner N. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin. Chem. 1997;43:1868-1876.
44. Al-Atrash G, Shetty S, Idell S, Xue Y, Kitson RP, Halady PK, Goldfarb RH. IL-2-mediated upregulation of uPA and uPAR in natural killer cells. Biochem. Biophys. Res. Commun. 2002;292:184-189.
45. Nykjaer A, Müller B, Tod, RF 3rd. Urokinase receptor. An activation antigen in human T lymphocytes. J. Immunol. 1994;152:505-516.
46. Shishido S, Satou H, Muramatsu M. Combination of pulse methylprednisolone infusions with cyclosporine-based immunosuppression is safe and effective to treat recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Clin. Transplant. 2013;27:E143-E150.
47. Park SJ, Saleem MA, Shin JI. Elevated soluble urokinase receptors in focal segmental glomerulosclerosis: a role for IL-2? Kidney Int. 2014;85:1469-1470.
48. Zhang B, Shi W, Ma J. The calcineurin-NFAT pathway allows for urokinase receptor-mediated beta3 integrin signaling to cause podocyte injury. J. Mol. Med (Berl). 2012;90:1407-1420.
49. Ranjan D, Chen C, Johnston TD. Curcumin inhibits mitogen stimulated lymphocyte proliferation, NFkB activation, and IL-2 signaling. J. Surg. Res. 2004;121:171-177.
50. Huang J, Liu G, Zhang YM, Cui Z, Wang F, Liu XJ, Chu R, Chen Y, Zhao MH. Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. Kidney Int. 2013;84:366-372.
51. Wei Y, Waltz DA, Rao N, Drummond RJ, Rosenberg S, Chapman HA. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 1994;269:32380-32388.
52. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F, Danø K. Cellular receptor for urokinase plasminogen activator. Carboxyl- terminal processing and membrane anchoring by glycosyl- phosphatidylinositol. J. Biol. Chem. 1991;266:1926-1933.
53. de Bock CE, Wang Y. Clinical significance of urokinasetype plasminogen activator receptor (uPAR) expression in cancer. Med. Res. Rev. 2004;24:13-39.
54. Estreicher A, Mühlhauser J, Carpentier JL, Orci L, Vassalli JD. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 1990;111:783-792.
55. Florquin S, van den Berg JG, Olszyna DP, Claessen N, Opal SM, Weening JJ, van der Poll T. Release of urokinase plasminogen activator receptor during urosepsis and endotoxemia. Kidney Int. 2001;59:2054-2061.
56. Grandahl-Hansen J, Lund LR, Ralfkiaer E, Ottevanger V, Danø K. Urokinase- and tissue-type plasminogen activators in keratinocytes during wound reepithelialization in vivo. J. Invest. Dermatol. 1988;90:790-795.
57. Thuno M, Macho B, Eugen-Olsen J. suPAR: the molecular crystal ball. Dis. Markers. 2009;27:157-172.
58. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J. Med. Virol. 2008;80:209-216.
59. Cunningham O, Andolfo A, Santovito ML, Iuzzolino L, Blasi F, Sidenius N. Dimerization controls the lipid raft partitioning of uPAR/CD87 and regulates its biological functions. EMBO J. 2003;22:5994-6003.
60. Fazioli F, Resnati M, Sidenius N, Higashimoto Y, Appella E, Blasi F. A urokinase-sensitive region of the human urokinase receptor is responsible for its chemotactic activity. EMBO J. 1997;16:7279-7286.
61. Høyer-Hansen G, Ploug M, Behrendt N, Ronne E, Danø K. Cell-surface acceleration of urokinase-catalyzed receptor cleavage. Eur. J. Biochem. 1997;243:21-26.
62. Beaufort N, Leduc D, Rousselle JC, Magdolen V, Luther T, Namane A, Chignard M, Pidard D. Proteolytic regulation of the urokinase receptor/CD87 on monocytic cells by neutrophil elastase and cathepsin G. J. Immunol. 2004;172:540-549.
63. Ossowski L, Aguirre-Ghiso JA. Urokinase receptor and integrin partnership: coordination of signaling for cell adhesion, migration and growth. Curr. Opin. Cell Biol. 2000;12:613-620.
64. Chapman HA. Plasminogen activators, integrins, and the coordinated regulation of cell adhesion and migration. Curr. Opin. Cell Biol. 1997;9:714-724.
65. Blasi F. uPA, uPAR, PAI-1: key intersection of proteolytic, adhesive and chemotactic highways? Immunol. Today. 1997;18:415-417.
66. Waltz DA, Natkin LR, Fujita RM, Wei Y, Chapman HA. Plasmin and plasminogen activator inhibitor type 1 promote cellular motility by regulating the interaction between the urokinase receptor and vitronectin. J. Clin. Invest. 1997;100:58-67.
67. Vaziri ND, Gonzales EC, Shayestehfar B, Barton CH. Plasma levels and urinary excretion of fibrinolytic and protease inhibitory proteins in nephrotic syndrome. J. Lab. Clin. Med. 1994;124:118-124.
68. Tudpor K, Lainez S, Kwakernaak AJ, Kovalevskaya NV, Verkaart S, van Genesen S, van der Kemp A, Navis G, Bindels RJ, Hoenderop JG. Urinary plasmin inhibits TRPV5 in nephrotic-range proteinuria. J. Am. Soc. Nephrol. 2012;23:1824-1834.
69. Andersen RF, Buhl KB, Jensen BL, Svenningsen P, Friis UG, Jespersen B, Rittig S. Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. Pediatr. Nephrol. 2013;28:1227-1234.
70. May AE, Kanse SM, Lund LR, Gisler RH, Imhof BA, Preissner KT. Urokinase receptor (CD87) regulates leukocyte recruitment via beta 2 integrins in vivo. J. Exp. Med. 1998;188:1029-1037.
71. Wei Y, Yang X, Liu Q, Wilkins JA, Chapman HA. A role for caveolin and the urokinase receptor in integrin-mediated adhesion and signaling. J. Cell. Biol. 1999;144: 1285-1294.
72. Wei Y, Eble JA, Wang Z, Kreidberg JA, Chapman HA. Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3beta1. Mol. Biol. Cell. 2001;12:2975-2986.
73. Warnock D, Kusche-Virog K, Tarjus A, Sheng Shaohu S, Oberleithner J, Kleyman TR, Jaisser F. Blood pressure and amiloride-sensitive sodium channels in vascular and renal cells. Nat. Rev. Nephrol. 2014;10:146-157.
74. Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, Brenner BM. Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J. Clin. Invest. 1983;71:91-103.
75. Vogt, B; Favre, H. Na+, K(+)-ATPase activity and hormones in single nephron segments from nephrotic rats. Clin. Sci (Lond). 1991;80:599-604.
76. Deschenes G, Doucet A. Collecting duct (Na+/K+)-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J. Am. Soc. Nephrol. 2000;11:604-615.
77. Deschenes G, Gonin S, Zolty E, Cheval L, Rousselot M, Martin PY, Verbavatz JM, Feraille E, Doucet A. Increased synthesis and avp unresponsiveness of Na, K-ATPase in collecting duct from nephrotic rats. J. Am. Soc. Nephrol. 2001;12:2241-2252.
78. Lourdel S, Loffing J, Favre G, Paulais M, Nissant A, Fakitsas P, Créminon C, Féraille E, Verrey F, Teulon J, Doucet A, Deschênes G. Hyperaldosteronemia and activation of the epithelial sodium channel are not required for sodium retention in puromycin-induced nephrosis. J. Am. Soc. Nephrol. 2005;16:3642-3650.
79. de Seigneux S, Kim SW, Hemmingsen SC, Frokiaer J, Nielsen S. Increased expression but not targeting of ENaC in adrenalectomized rats with PAN-induced nephrotic syndrome. Am. J. Physiol. Renal Physiol. 2006;291:F208-217.
80. Kim SW, Wang W, Nielsen J, Praetorius J, Kwon TH, Knepper MA, Frøkiaer J, Nielsen S. Increased expression and apical targeting of renal ENaC subunits in puromycin aminonucleoside-induced nephrotic syndrome in rats. Am. J. Physiol. Renal Physiol. 2004;286:F922-935.
81. Snyder PM. Minireview: regulation of epithelial Na+ channel trafficking. Endocrinology. 2005;146:5079-5085.
82. Hamm LL, Feng Z, Hering-Smith KS. Regulation of sodium transport by ENaC in the kidney. Curr. Opin. Nephrol. Hypertens. 2010;19:98-105.
83. Ma HP, Eaton DC. Acute regulation of epithelial sodium channel by anionic phospholipids. J. Am. Soc. Nephrol. 2005;16:3182-3187.
84. Oliver WJ. Physiologic responses associated with steroid-induced diuresis in the nephrotic syndrome. J. Lab. Clin. Med. 1963;62:449-464.
85. Koomans HA, Boer WH, Dorhout Mees EJ. Renal function during recovery from minimal lesions nephrotic syndrome. Nephron. 1987;47:173-178.
86. Brown EA, Markandu N, Sagnella GA, Jones BE, MacGregor GA. Sodium retention in nephrotic syndrome is due to an intrarenal defect: evidence from steroid-induced remission. Nephron. 1985;39:290-295.
87. Kumagai H, Onoyama K, Iseki K. Role of renin angiotensin aldosterone on minimal change nephrotic syndrome. Clin. Nephrol. 1985;23:229-235.
88. Oliver WJ, Owings CL. Sodium excretion in the nephrotic syndrome. Relation to serum albumin concentration, glomerular filtration rate, and aldosterone excretion rate. Am. J. Dis. Child. 1967;113:352-362.
89. Hoenderop JG, van der Kemp AW, Hartog A, van de Graaf SF, van Os CH, Willems PH, Bindels RJ. Molecular identification of the apical Ca2+ channel in 1, 25-dihydroxyvitamin D3-responsive epithelia. J. Biol. Chem. 1999;274:8375-8378.
90. Lambers TT, Weidema AF, Nilius B, Hoenderop JG, Bindels RJ. Regulation of the mouse epithelial Ca2(+) channel TRPV6 by the Ca(2 +)-sensor calmodulin. J. Biol. Chem. 2004;279:28855-28861.
91. Nilius B, Vennekens R, Prenen J, Hoenderop JG, Droogmans G, Bindels RJ. The single pore residue Asp542 determines Ca2+ permeation and Mg2+ block of the epithelial Ca2+ channel. J. Biol. Chem. 2001;276:1020-1025.
92. de Groot T, Lee K, Langeslag M, Xi Q, Jalink K, Bindels RJ, Hoenderop JG. Parathyroid hormone activates TRPV5 via PKA-dependent phosphorylation. J. Am. Soc. Nephrol. 2009;20:1693-1704.
93. Gkika D, Topala CN, Chang Q, Picard N, Thebault S, Houillier P, Hoenderop JG, Bindels RJ. Tissue kallikrein stimulates Ca(2+) reabsorption via PKC-dependent plasma membrane accumulation of TRPV5. EMBO J. 2006;25:4707-4716.
94. Kuusniemi AM, Lapatto R, Holmberg C, Karikoski R, Rapola J, Jalanko H. Kidneys with heavy proteinuria show fibrosis, inflammation, and oxidative stress, but no tubular phenotypic change. Kidney Int. 2005;68:121-132.
95. Burke EC, Holley KE, Stickler GB. Familial nephrotic syndrome with nephrocalcinosis and tubular dysfunction. J. Pediatr. 1973, 82:202-206.
96. Mocan H, Yildiran A, Camlibel T, Kuzey GM. Microscopic nephrocalcinosis and hypercalciuria in nephrotic syndrome. Hum. Pathol. 2000;31:1363-1367.
97. Alexander RT, Woudenberg-Vrenken TE, Buurman J, Dijkman H, van der Eerden BC, van Leeuwen JP, Bindels RJ, Hoenderop JG. Klotho prevents renal calcium loss. J. Am. Soc. Nephrol. 2009;20:2371-2379.
98. Passero CJ, Mueller GM, Rondon-Berrios H, Tofovic SP, Hughey RP, Kleyman TR. Plasmin activates epithelial Na+ channels by cleaving the gamma subunit. J. Biol. Chem. 2008;283:36586-36591.
99. Oberleithner H, Kusche-Vihrog K, Schillers H. Endothelial cells as vascular salt sensors. Kidney Int. 2010;77:490-494.
100. Schiffrin EL. Effects of aldosterone on the vasculature. Hypertension. 2006;47:312-318.
101. Perez FR, Venegas F, Gonzalez M. Endothelial epithelial sodium channel inhibition activates endothelial nitric oxide synthase via phosphoinositide 3-kinase/Akt in small-diameter mesenteric arteries. Hypertension. 2009;53:1000-1007.
102. Fujiwara N, Osanai T, Kamada T. Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation. 2000;101:856-861.
103. Li J, White J, Guo L, Zhao X, Wang J, Smart EJ, Li XA. Salt inactivates endothelial nitric oxide synthase in endothelial cells. J. Nutr. 2009;139:447-451.
104. Kasas S, Wang X, Hirling H. Superficial and deep changes of cellular mechanical properties following cytoskeleton disassembly. Cell Motil. Cytoskeleton. 2005;62:124-132.
105. Pesen D, Hoh JH. Micromechanical architecture of the endothelial cell cortex. Biophys. J. 2005;88:670-679.
106. Oberleithner H, Callies C, Kusche-Vihrog K, Schillers H, Shahin V, Riethmüller C, Macgregor GA, de Wardener HE. Potassium softens vascular endothelium and increases nitric oxide release. Proc. Natl. Acad. Sci. U S A. 2009;106:2829-2834.
107. Su Y, Edwards-Bennett S, Bubb MR, Block ER. Regulation of endothelial nitric oxide synthase by the actin cytoskeleton. Am. J. Physiol. Cell Physiol. 2003;284:C1542-1549.
108. Rizzo V, McIntosh DP, Oh P, Schnitzer JE. In situ flow activates endothelial nitric oxide synthase in luminal caveolae of endothelium with rapid caveolin dissociation and calmodulin association. J. Biol. Chem. 1998;273:34724-34729.
109. Vrbka L, Vondrsek J, Jagoda-Cwiklik B, Vcha R, Jungwirth P. Quantification and rationalization of the higher affinity of sodium over potassium to protein surfaces. Proc. Natl. Acad. Sci. U S A. 2006;103:15440-15444.
110. Salmon AHJ, Ferguson JK, Burford JL, Gevorgyan H, Nakano D, Harper SJ, Bates DO, Peti-Peterdi J. Loss of the endothelial glycocalyx links albuminuria and vascular dysfunction. J. Am. Soc. Nephrol. 2012;23:1339-1350.
111. Kumagai R; Lu X, Kassab GS. Role of glycocalyx in flow-induced production of nitric oxide and reactive oxygen species. Free Radic. Biol. Med. 2009;47:600-607.
112. Michel CC, Curry FE. Microvascular permeability. Physiol. Rev. 1999;79:703-761.
113. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu. Rev. Biomed. Eng. 2007;9:121-167.
114. Nagy N, Freudenberger T, Melchior-Becker A, Röck K, Ter Braak M, Jastrow H, Kinzig M, Lucke S, Suvorava T, Kojda G, Weber AA, Sörgel F, Levkau B, Ergün S, Fischer JW. Inhibition of hyaluronan synthesis accelerates murine atherosclerosis. Novel insights into the role of hyaluronan synthesis. Circulation. 2010;122:2313-2322.
115. Reubi FC, Weidmann P, Gluck Z. Interrelationships between sodium clearance, plasma aldosterone, plasma renin activity, renal hemodynamics and blood pressure in renal disease. Klin. Wochenschr. 1979;57:1273-1285.
116. Deschenes G, Feraille E, Doucet A. Mechanisms of edema in nephrotic syndrome: old theories and new ideas. Nephrol. Dial. Transplant. 2003;18:454-456.